Singapore markets closed

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.0600-0.0200 (-1.85%)
As of 09:33AM EDT. Market open.

Adaptimmune Therapeutics plc

60 Jubilee Avenue
Milton Park
Abingdon OX14 4RX
United Kingdom
44 12 3543 0000
https://www.adaptimmune.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees449

Key executives

NameTitlePayExercisedYear born
Mr. Adrian G. RawcliffeCEO, Principal Accounting Officer & Director1.06M199.16k1972
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.Co-Founder & Chief Business & Strategy Officer677.4kN/A1967
Mr. Gavin Hilary James Wood ACA, BA (Hons)Chief Financial Officer666.34kN/A1970
Mr. William C. Bertrand Jr., Esq., J.D.Chief Operating Officer707.34k76.95k1965
Dr. Elliot Norry B.A., M.D.Chief Medical Officer676.19k65.02k1964
Ms. Joanna Brewer Ph.D.Chief Scientific OfficerN/AN/A1976
Dr. Juli P. Miller Ph.D.VP of Corporate Affairs & Investor RelationsN/AN/AN/A
Ms. Kerry SharpSenior VP & General CouncilN/AN/AN/A
Dana LynchSenior Director of Corporate CommunicationsN/AN/AN/A
Mr. John LungerChief Patient Supply Officer645.91k148.2k1970
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Corporate governance

Adaptimmune Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.